The FDA 'Bad Ad' Program — Us Vs. Them

Law360, New York (May 20, 2010, 12:04 PM EDT) -- Citing a limited ability to identify violative pharmaceutical advertising and promotional activities, the Food and Drug Administration has announced the launch of its “Bad Ad” Program. The program encourages health care providers to directly report potentially false or misleading prescription drug advertising, marketing materials and promotional activities to the FDA.

Under the new program, the Division of Drug Marketing, Advertising and Communications (DDMAC) also will work with and train health care providers to recognize and report allegedly unlawful activities. Specifically, the DDMAC encourages prescribers to look...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.